Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tampa, Florida 33612


Purpose:

Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may increase the effectiveness of flavopiridol by making cancer cells more sensitive to the drug. Giving bortezomib together with flavopiridol may kill more cancer cells. This phase I trial is studying the side effects and best dose of bortezomib and flavopiridol in treating patients with recurrent or refractory indolent B-cell neoplasms.


Study summary:

PRIMARY OBJECTIVES: I. To determine the recommended phase II dose of bortezomib and flavopiridol in patients with recurrent or refractory indolent B-cell neoplasms. SECONDARY OBJECTIVES: I. To determine the toxic effects and maximum tolerated dose of this regimen in these patients. II. To determine disease-related effects of this regimen in these patients. III. To determine the pharmacodynamics of this regimen in patients with myeloma. IV. To determine the pharmacokinetics of this regimen in these patients. OUTLINE: This is a dose-escalation, multicenter study. Patients receive bortezomib IV over 3-5 seconds followed by flavopiridol IV over 1 hour on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.


Criteria:

Inclusion Criteria: - WBC < 50,000/mm^3 for patients with circulating tumor cells - No prior allergic reaction to compounds of similar chemical or biological composition to and presumably able to tolerated bortezomib, flavopiridol, allopurinol, sodium polystyrene sulfonate, or dexamethasone - No neuropathy >= grade 2 - No other condition that would preclude study participation - Not pregnant or nursing - Fertile patients must use effective contraception during and for 3 months after study participation - Prior autologous stem cell transplantation is allowed - No prior allogeneic stem cell transplantation - No other concurrent anticancer agents - No other concurrent investigational agents - Hemoglobin >= 8 g/dL - Platelet count >= 100,000/mm^3 - Absolute neutrophil count >= 1,500/mm^3 - Bilirubin =< 2 times upper limit of normal (ULN) - AST/ALT =< 3 times ULN - Creatinine =< 2 times ULN or Creatinine clearance >= 50 mL/min


NCT ID:

NCT00082784


Primary Contact:

Principal Investigator
Steven Grant
Moffitt Cancer Center


Backup Contact:

N/A


Location Contact:

Tampa, Florida 33612
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.